GAIASO Appoints Tracey Brown Chief Executive Officer

GAIASO has appointed Dr. Tracey Brown as its new Chief Executive Officer. Her appointment strengthens GAIASO’s mission to advance next-generation precision radiopharmaceuticals and deliver meaningful impact for patients.

As a biotech entrepreneur, Brown is recognized for transforming science into real-world products, with a track record of clear strategy, collaborative leadership, and disciplined execution in resource-constrained, high-growth settings. 

Brown brings extensive international experience across oncology and radiopharmaceutical development. She has held senior leadership roles at Telix Pharmaceuticals, Anatara Lifesciences, and Alchemia, where she drove product development. 

Earlier, she co-founded Meditech Research, inventing the pioneering HyACT oncology drug-delivery platform and building a substantial patent estate while leading the portfolio strategy. She began her career at Monash University, where she led the Hyaluronan Laboratory and held research and adjunct appointments. 

Professor Rod Hicks, Chief Medical Officer, commented: “We are delighted to welcome Tracey as GAIASO’s new CEO. Her outstanding track record in leading complex global clinical programs, combined with her pioneering work in oncology drug development, makes her uniquely placed to guide our company into its next phase. Tracey’s vision and passion for improving patient outcomes perfectly align with GAIASO’s mission to redefine cancer care.”